- Marinus Pharmaceuticals ( NASDAQ: MRNS ) stock dropped 19% postmarket on Monday after the firm announced an underwritten public offering of its securities.
- Underwriters will have a 30-day option to buy up to an additional 15% of the number of securities in the offering at the public offering price.
- Marinus ( MRNS ) intends to use the net proceeds to continue to fund commercialization of ZTALMY (ganaxolone) oral suspension CV, development of its product candidates and for general corporate purposes.
- The drugmaker also reported Q3 results .
For further details see:
Marinus Pharmaceuticals stock drops 19% aftermarket on proposed public offering